Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
FDA revokes breakthrough status for BMS hep C drug

The big biotech tells FierceBiotech in a statement that the agency has "informed Bristol-Myers Squibb that, due to the evolving HCV treatment landscape, the agency intends to rescind the breakthrough therapy designation for certain genotype 1 hepatitis C regimens related to daclatasvir." Bristol-Myers then went on to add that the decision will not impact its timetable on an NDA for daclatasvir, which faces a unique set of challenges all its own.

Published
11 February 2015
From
Fierce Biotech
Dutrebis, New HIV Drug, Approved by FDA, but Not Commercially Available

The new combination contains 150 mg of lamivudine (3TC, Epivir) and 300 mg of raltegravir (Isentress). Despite the FDA approval, the drug manufacturer, Merck Pharmaceuticals, announced that they would not be making Dutrebis commercially available in the U.S. at this time.

Published
11 February 2015
From
The Body Pro
A more personalised approach to hepatitis C treatment may improve adherence and completion rates

People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as

Published
11 February 2015
By
Roger Pebody
Gilead faces challenge to European patent on pricey hep C drug

Global health charity Medecins du Monde (MdM) launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug.

Published
10 February 2015
From
Reuters
Worldwide treatment of hepatitis C could be within sight at the right cost

Lowering the cost of hepatitis C drugs is possible and it is key to achieving global access to treatment, according to new research.

Published
09 February 2015
From
Imperial College press release
Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB

President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts, boost spending for HIV research, and allocate more to combat antibiotic resistance. But the plan would cut overall global health funding, including support for the Global Fund to Fight AIDS, Malaria, and Tuberculosis.

Published
09 February 2015
From
HIVandHepatitis.com
Even After Obamacare, It's Still Way Too Hard To Get HIV Meds

Seeking a better, safer sex life, people are using open enrollment to switch their health plans to ones that bring Truvada in reach. If only it were that simple.

Published
09 February 2015
From
Daily Beast
Exploring common contributors to reducing HIV infections

Researchers looking for common factors associated with declining HIV infections in four diverse jurisdictions observed that strong leadership within state and local health departments was the most notable unifying factor critical to programmatic success in each of the two states and two cities studied: North Carolina, San Francisco, Massachusetts and Seattle.

Published
09 February 2015
From
HIV / AIDS News From Medical News Today
Portugal agrees to treat 13,000 hepatitis C patients

The Portuguese government has agreed to treat up to 13,000 people infected with hepatitis C in the next three years, Portuguese Minister of Health Paulo Macedo said on Friday.

Published
09 February 2015
From
Xinhua
VOICE trial: Microbicide gel may have stopped two out of three HIV infections – in the women who used it

The final published paper on the VOICE trial in women in three African countries mainly reinforces what conference presentations have already shown: this ambitious trial failed to

Published
09 February 2015
By
Gus Cairns

Filter by country